PET-CTDYNAMETNCT07676448
Performance of Amino Acid Positons Emission Tomography in Brain Metastases
An observational study of PET-CT, run by Central Hospital, Nancy, France.
Trial summary
Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- PET-CT
- What is being tested?
- PET exam analysis
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 5 Aug 2026to 3 Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients referred for amino acid PET imaging in the Nuclear Medicine Department of Nancy University Hospital for the differential diagnosis between radiation necrosis and brain tumor progression between November 1, 2018, and April 30, 2026.
Who may be able to join
- Patients who received a PET amino acid for differentiating radiation necrosis from progression of irradiated brain metastases,
Who cannot join
- Patients who refused the using of their data
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Static and Dynamic Performance of Amino Acid Positons Emission Tomography (PET) for Differentiating Radiation Necrosis From Tumor Progression in Irradiated Brain Metastases (DYNAMET)
Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications
Read the detailed description
Differentiating radiation necrosis from tumor progression in patients with brain metastases treated with radiotherapy is a major challenge in post-treatment management, as the therapeutic and prognostic implications differ substantially depending on whether the lesion represents radiation necrosis (surveillance, anti-angiogenic therapy) or tumor progression (re-initiation of local or systemic treatment).
In addition to brain MRI, amino acid PET imaging, including both static and dynamic acquisitions, is a key diagnostic tool for this purpose.
However, the added value of dynamic acquisitions remains uncertain, and the available evidence is limited to small patient series.
- Conditions
- PET-CT
- Being tested
- PET exam analysis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PET exam analysisDiagnostic test
static and dynamic analyses
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare the diagnostic performance amino acid PET imaging
Uptake of tumor
Measured: Day 1
Secondary outcomes (1)
To evaluate the potential impact of immunotherapy administered before or during PET imaging
MRI results
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2026
- Study start5 Aug 2026 (estimated)
- Primary completion3 Sep 2026 (estimated)
- Study completion3 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PET-CTStudies of the same condition, open and under way.
- More trials run by Central Hospital, Nancy, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Antoine VERGER, Central Hospital, Nancy, France
- Investigators
- Antoine AV VERGER, MD, PhD, Principal investigator, NANCY HOSPITAL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07676448
- Sponsor's protocol ID
- 2026PI251
- Acronym
- DYNAMET
- Status last verified
- Jul 2026
- First submitted
- 24 Jun 2026
- Last updated
- 17 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Static and Dynamic Performance of Amino Acid Positons Emission Tomography (PET) for Differentiating Radiation Necrosis From Tumor Progression in Irradiated Brain Metastases (DYNAMET)
- ClinicalTrials.gov ID
- NCT07676448
- Acronym / sponsor ID
- DYNAMET / 2026PI251
- Conditions
- PET-CT
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- 5 Aug 2026 (estimated)
- Primary completion
- 3 Sep 2026 (estimated)
- Study completion
- 3 Nov 2026 (estimated)
- First posted
- 30 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications
Detailed description
Differentiating radiation necrosis from tumor progression in patients with brain metastases treated with radiotherapy is a major challenge in post-treatment management, as the therapeutic and prognostic implications differ substantially depending on whether the lesion represents radiation necrosis (surveillance, anti-angiogenic therapy) or tumor progression (re-initiation of local or systemic treatment).
In addition to brain MRI, amino acid PET imaging, including both static and dynamic acquisitions, is a key diagnostic tool for this purpose.
However, the added value of dynamic acquisitions remains uncertain, and the available evidence is limited to small patient series.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients referred for amino acid PET imaging in the Nuclear Medicine Department of Nancy University Hospital for the differential diagnosis between radiation necrosis and brain tumor progression between November 1, 2018, and April 30, 2026.
Key inclusion criteria (1 listed)
- Patients who received a PET amino acid for differentiating radiation necrosis from progression of irradiated brain metastases,
Key exclusion criteria (1 listed)
- Patients who refused the using of their data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PET exam analysisstatic and dynamic analyses | Diagnostic test | – |
Primary outcome
To compare the diagnostic performance amino acid PET imaging
Time frame: Day 1
Uptake of tumor
1 secondary outcome
To evaluate the potential impact of immunotherapy administered before or during PET imaging
Time frame: 2 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
Related trials for PET-CT
RecruitingPhase 2
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
Soft Tissue Sarcoma
Recruiting
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
Prostate Cancer (Diagnosis), ACP3
Active, not recruitingEarly Phase 1
Clinical Study of 68Ga-labeled Novel EPHA2 Cyclic Peptides PET/CT for Imaging of Solid Tumors
Solid Tumor Malignancies
RecruitingPhase 1
First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers
Healthy
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Antoine AV VERGER, MD, PhD principal investigator
NANCY HOSPITAL
Questions about this trial
What is this clinical trial studying?
An observational study of PET-CT, run by Central Hospital, Nancy, France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lucas LW WILHELM, MD (0383153911 ext. +33, l.wilhelm@chru-nancy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare the diagnostic performance amino acid PET imaging (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.